
# EXHIBIT 8

Name: Hilary Converse | DOB: 40/10/1016 | MRN: MR814530 | PCP: Stephanie Ann Parrillo, PA

# **Appointment Details**

Notes



Shared Notes FAQ || Link to common abbreviations || Link to Health Topics Search

# **Progress Notes**

Peter E Schwartz at 9/25/2020 9:30 AM

Re: Hilary Converse (40/20/4040)

MRN: MR814530

Provider: Peter E Schwartz, MD

Referring Provider: Parrillo, Stephanie Ann, Pa

2560 Dixwell Ave

Ste 2b

Hamden, CT 06514-1852

Primary Care Provider: Parrillo, Stephanie Ann

Date of service: 9/25/2020

REASON FOR VISIT: Follow-up

Chief Complaint: Encounter Diagnosis

Malignant neoplasm of left ovary (HC Code)

Primary? Yes

INTERIM HISTORY: The patient is a 71-year-old woman who had a telephone appointment with me today for followup of her stage IA clear cell cancer of the left ovary that was diagnosed on September 5, 2007, when the patient underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic and periaortic lymphadenectomies. Postoperatively, the patient received 6 cycles of carboplatin and Taxol. The patient has remained clinically free of disease thereafter. The patient reports today that she is doing well during the COVID pandemic. However, she has been gaining weight. She reports no change in her bowel or urinary habits, but does note that she has irritable bowel syndrome for which she has a loperamide prescription for management of symptoms and she has interstitial cystitis which can cause urinary symptoms. She denies any vaginal spotting or bleeding. She has not had any abdominal bloating. She has no shortness of breath or chest pain. The patient is up to date with mammography. Her last mammogram was on March 4, 2020, and was BI-RADS 1. She also has had an MRI on October 7, 2019. It was BI-RADS 2. The patient's most recent CA-125 was September 20, 2019. It was 6.3 units/mL. The patient is due for a CA-125 determination.

Document 33111-9 Filed 08/22/24 Case 3:16-md-02738-MAS-RLS Page 3 of 7 PageID: 229761

PAST HISTORY:

**Past Medical History:** 

Diagnosis

Fibromyalgia

 Hemia Hernia

Migraines

 Ovarian cancer (HC Code) 1A s/p chemo

Shingles

Date

8/9/2013 8/9/2013

01/2007-2008

Past Surgical History:

Procedure

ADENOIDECTOMY

CERVICAL FUSION

COLONOSCOPY

HERNIA REPAIR

 HYSTERECTOMY bilateral oopherectomy

· ovarian cancer

Laterality

Dispense

Date

Refill

0

**Current Outpatient Medications** 

Medication

tablet

ALPRAZolam (XANAX) 0.5 MG

0.5 mg.. 1/2 am, 1/2

 ascorbic acid, vitamin C, (VITAMIN C) 1000 MG tablet

 CYCLOBENZAPRINE HCL (FLEXERIL ORAL)

noon, 1 at bedtime. Take 1,000 mg by mouth daily..

Take 5 mg by mouth... 1/2 3 times a day, 2 at

bedtime

Sig

diazePAM (VALIUM) 10 MG tablet

Take 10 mg by mouth as needed (Prior to dental visit)...

mouth once a week ...

2 (two) times a day.

Take 50,000 Units by

 ergocalciferol (VITAMIN D2) 50,000 unit capsule esomeprazole (NEXIUM) 40 MG

PF, injection

TO BE ADMINISTERED BY

PHARMACIST FOR **IMMUNIZATION** Take by mouth.

FUROSEMIDE (LASIX ORAL)

glucosamine-chondroitin 500-400

FLUZONE HIGH-DOSE 2017-18.

mg Cap

 HYDROcodone-acetaminophen (NORCO) 7.5-325 mg per tablet

HYDROXYZINE HCL ORAL

Take 1 tablet by mouth

as needed ..

Take by mouth..

Take 25 mg by mouth

Nightly...

· loperamide (IMODIUM) 2 mg capsule

Take 2 mg by mouth 4 (four) times daily as needed for Diarrhea.. Take 27.5 mg by

 magnesium gluconate (MAGONATE) 27.5 mg (500 mg)

meloxicam (MOBIC) 7.5 MG tablet 15 mg as needed..

mouth daily...

multivitamin capsule

Take 1 capsule by mouth daily.. Take by mouth..

 nitrofurantoin (MACRODANTIN) 50 MG capsule

 POTASSIUM CHLORIDE (KLOR-CON ORAL)

PROCHLORPERAZINE

Take by mouth as

Take by mouth.

CONVERSE\_HILARY\_DRPETERSCHWARTZ\_00126

https://mychart.ynhhs.org/MyChart-PRD/inside.asp?mode=visitsummary&submode=notes&csn=c60NrqhN6WhREINdShfjfg%3d%3d

11/25/2020

Document 33111-9 Filed 08/22/24 Case 3:16-md-02738-MAS-RLS MALEATE (COMPAZINE ORAL) Page 4 of 7 needge ID: 229762

propranolol (INDERAL LA) 60 MG

24 hr capsule

sertraline (ZOLOFT) 100 MG

100 mg daily.

tablet

tiZANidine (ZANAFLEX) 2 MG

1 at dinner, 2 at

capsule

bedtime

VAGIFEM 10 mcg Tab

Twice a week

No current facility-administered medications for this visit.

**Allergies** 

Allergen

Reactions Sulfa (Sulfonamide Antibiotics) Hives and Rash Lactose Intolerance [Lactase] **GI Upset** 

Bacitracin

Rash Rash

 Neosporin [Benzalkonium Chloride] Other

**Nausea And Vomiting** 

scallops

**Social History** 

Tobacco Use

Smoking status:

Former Smoker

Quit date:

1/22/1998

Years since quitting: Smokeless tobacco:

22.6 **Never Used** 

Substance Use Topics

· Alcohol use:

Yes

Comment: 3 times a week

**Family History** 

Problem.

Relation

Age of Onset

Cancer, Non-Melanoma Skin Cancer

Mother

Breast cancer

Mother Father

 Lung cancer Pancreatic cancer

Maternal Grandmother

ROS:

Constitutional: No weight loss, no worsening fatigue

Eyes: No visual problems, no eye discharge, no eye pain

Skin: No rashes, no lesions, no hypo or hyperpigmentation

Ears/Nose/Throat: No nasal discharge, no throat pain, no hearing loss/difficulty, no tinnitus

Gastrointestinal: No nausea, no vomiting, diarrhea or reflux

Chest: No chest pain, no cough, no sputum production

Muscular: No muscle pain, no muscle weakness

Neurological: No dysarthria, No arm or leg weakness, no visual disturbances, no gait

disturbances

Genitourinary: No vaginal discharge, bleeding, no urinary frequency, dysuria, no nocturia, no

hematuria

Endocrine: No neck swelling, no polydypsia, polyphagia, no polyuria, no galactorrhea

Breast-No masses or discharge; up to date with mammograms

Mental Status: No confusion, no memory loss, no word finding difficulties

immunology: No enlarged lymph nodes

CONVERSE\_HILARY\_DRPETERSCHWARTZ\_00127

Case 3:16-md-02738-MAS-RLS Document 33111-9 Filed 08/22/24 Page 5 of 7 Cardiovascular: No palpitations, no issue wellings 703SOB, no orthopnea, no paroxysmal nocturnal dyspnea.

Hematology/Lymph: No syncope, no fatigue, no bone pain

#### PHYSICAL EXAM:

There were no vitals taken for this visit.

A physical examination was not performed today as this was a telephone appointment.

ASSESSMENT/PLAN: My impression is the patient is doing well. She has no symptoms for recurrent ovarian cancer. We will schedule a CA-125 for her, at Quest Lab in Cheshire, Connecticut. The patient has also requested a Vagifem prescription be either emailed or faxed to Medix, a pharmaceutical company in England, who provides this to her. Their fax number is 866 335-9270, or their email address is info@medixx.com. The patient uses 10 mcg of Vagifem twice a week. The prescription should have 24 tablets. The patient also had a long discussion with me about her daughter and prophylactic surgery because the patient's family history suggests that the patient's family members are at increased risk for breast and ovarian cancer. She notes that a grandmother had pancreatic cancer. Her mother had premenopausal breast cancer, and of course, she herself has ovarian cancer. I recommended that the patient contact the genetics counselor, as her last BRCA gene mutation determination, which was negative, was performed back 13 years ago, and based on that, any further recommendations for her daughter regarding additional testing or prophylactic surgery can develop. I did give her the name of Dr. Elena Ratner should her daughter require surgery. All the patient's questions were answered. The patient will return in 6 months for routine followup.

Peter E Schwartz, MD, MD

Electronically Signed by Peter E Schwartz, MD, September 25, 2020

TELEPHONE VISIT: For this visit the clinician and patient were present via telephone (audio only). Patient counseled on available options for visit type; Patient elected telephone visit; Patient consent given for telephone visit: YES Patient Identity was confirmed during this call.

Other individuals actively participating in the telephone encounter and their name/relation to the patient: none

Total time spent in medical telephone consultation: 20 minutes

Because this visit was completed over telephone, a hands-on physical exam was not performed. Patient understands and knows to call back if condition changes.

The visit type for this patient required modifications due to the COVID-19 outbreak.

MyChart® licensed from Epic Systems Corporation © 1999 - 2020

CONVERSE\_HILARY\_DRPETERSCHWARTZ\_00129

Name: Hilary Converse | DOB: 10/10/1016 | MRN: MR814530 | PCP: Stephanie Ann Parrillo, PA

## **CANCER ANTIGEN 125 - Details**

## **Component Results**

Component

Your Value

Standard Range

CA 125 (Q)

Your Value

Standard Range

5 U/mL

<35 U/mL

This test was performed using the Beckman Coulter Chemiluminescent method. Values obtained from different assay methods cannot be used interchangeably. CA 125 levels, regardless of value, should not be interpreted as absolute evidence of the presence or absence of disease.

### General Information

Ordered by Jamie Malette, APRN

Collected on 09/29/2020 12:37 PM (Blood)

Resulted on 10/01/2020 7:15 AM

Result Status: Final result

MyChart® licensed from Epic Systems Corporation @ 1999 - 2020